Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH)
INGELHEIM, Germany & CAMBRIDGE, Mass. -- (BUSINESS WIRE) --
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment.
The option is the second target under the two companies’ research collaboration and license agreement. Under the terms of the agreement, Boehringer Ingelheim will be responsible for future clinical development and commercialization of the therapeutic target. Dicerna is eligible to receive development and commercial milestone payments, and royalties on worldwide net sales.
“It is extremely gratifying for Boehringer Ingelheim to exercise its option for a second therapeutic candidate from our productive research collaboration,” said Douglas M. Fambrough, President and Chief Executive Officer of Dicerna. “The option exercise underscores the potential of Dicerna’s GalXC technology platform in facilitating the discovery and development of novel RNAi therapies for nonalcoholic steatohepatitis and other chronic liver diseases. We look forward to continued progress and the potential advancement of clinical candidates from our partnership.”
Dicerna and Boehringer Ingelheim selected the target based on its ability to be drugged using Dicerna’s proprietary GalXC technology platform. The GalXC platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. The approach has the potential to treat diseases by silencing previously inaccessible drug targets.
“Boehringer Ingelheim is pleased with the progress of our initial collaboration with Dicerna and based on early findings and our strong relationship, we are expanding our research efforts,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “Today’s announcement exemplifies our commitment to discovering new therapies for NASH and other chronic liver diseases and advances our research efforts in this priority area.”
NASH is caused by the buildup of fat in the liver, potentially leading to liver fibrosis and cirrhosis. It has an especially high prevalence among obese and diabetic patients and is an area of high unmet medical need. NASH is expected to soon become the most common cause of advanced liver disorders, and it often necessitates liver transplantation.
Dicerna is building a portfolio of research and development programs to advance the treatment of diseases involving the liver, including chronic liver diseases, viral infectious diseases, cardiovascular diseases and rare diseases. The company aims to leverage its proprietary GalXC technology to develop innovative RNAi therapeutics to positively transform the lives of individuals living with these diseases.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking statements include, among others, statements Dicerna makes regarding: (i) the therapeutic and commercial potential of GalXC™; (ii) research and development plans related to GalXC; and (iii) the potential of our technology and drug candidates in our research and development pipeline. The process by which an early stage platform such as GalXC could potentially lead to an approved product is long and subject to highly significant risks, particularly with respect to a pre-clinical research collaboration. Applicable risks and uncertainties include those relating to Dicerna’s preclinical research and other risks identified under the heading "Risk Factors" included in Dicerna’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
金秋最艳丽的红色—中国最北海岸线,天下奇观
轻触乘车!Monterey-Salinas Transit
“亲有疾 药先尝 昼夜侍 不离床”——国旗
ROSEN鼓励投资者在SQ证券集体诉讼重要截止日期
十三届全国人大常委会第二十三次会议在京闭幕
上饶市龙潭湖酒店集团开展爱心助学行动
2023年中国高考:英语教育的挑战与机遇
Canva推出全球开发者平台、5000万美元基金和全新
InsidePacket扩展SONiC用例以支持新的边缘
郴州市娄底商会成立大会召开
INNIO将为Raven SR的废物制氢厂提供可再生能源支
上饶首笔公积金“亮码可办”业务在信州分中心
上饶公积金:便民惠民跑出“加速度”
Energy Vault和Jupiter Power宣布就
NIPPON Platform Co., Ltd
PLDA宣布全面支持CXL 和Gen-Z 协议
江西广丰:桃园成网红地
西安:让生态流入城市 “茉莉花”般沁人心脾
女人文胸穿不对,极易被“乳腺癌”盯上?辛明
赣州首家“互联网➕”家政服务平台在沪挂牌上
SYNTAGMA CAPITAL已就收购Lennox
国务院联防联控机制:核酸检测要力争6小时内
滨州市启动全市学校(校车)安全生产专项整治
江西婺源:四省五地农民画 记录山乡巨变